CZO:CA:CDX-Ceapro Inc. (CAD)

COMMON STOCK | Biotechnology | TSX Venture Exchange

Last Closing

USD 0.235

Change

-0.01 (-2.08)%

Market Cap

USD 0.10B

Volume

0.07M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ceapro Inc is a biotechnology company. It is engaged in the marketing and development of health and wellness products and technology relating to plant extracts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NGEN:CA NervGen Pharma Corp

N/A

USD 0.16B
ARCH:CA Arch Biopartners Inc

N/A

USD 0.12B
MIR:CA MedMira Inc

N/A

USD 0.05B
NRX:CA NurExone Biologic Inc.

N/A

USD 0.04B
TTI:CA Thiogenesis Therapeutics Corp.

N/A

USD 0.03B
GSD:CA Devonian Health Group Inc

N/A

USD 0.03B
COV:CA Covalon Technologies Ltd.

N/A

USD 0.03B
KNE:CA Kane Biotech Inc

N/A

USD 0.02B
XRTX:CA XORTX Therapeutics Inc

N/A

USD 0.02B
ZENI-P:CA Zenith Capital Corporation

N/A

USD 0.02B

ETFs Containing CZO:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (TSX Venture Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.68% 57% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.68% 57% F 76% C+
Trailing 12 Months  
Capital Gain -63.85% 26% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.85% 26% F 16% F
Trailing 5 Years  
Capital Gain -36.49% 56% F 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.49% 56% F 51% F
Average Annual (5 Year Horizon)  
Capital Gain 16.09% 71% C- 67% D+
Dividend Return 16.09% 71% C- 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 66.60% 29% F 39% F
Risk Adjusted Return 24.16% 71% C- 69% C-
Market Capitalization 0.10B 63% D 69% C-

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector